206 related articles for article (PubMed ID: 23713800)
1. Structure-based drug design of catechol-O-methyltransferase inhibitors for CNS disorders.
Ma Z; Liu H; Wu B
Br J Clin Pharmacol; 2014 Mar; 77(3):410-20. PubMed ID: 23713800
[TBL] [Abstract][Full Text] [Related]
2. Bisubstrate inhibitors for the enzyme catechol-O-methyltransferase (COMT): influence of inhibitor preorganisation and linker length between the two substrate moieties on binding affinity.
Lerner C; Masjost B; Ruf A; Gramlich V; Jakob-Roetne R; Zürcher G; Borroni E; Diederich F
Org Biomol Chem; 2003 Jan; 1(1):42-9. PubMed ID: 12929389
[TBL] [Abstract][Full Text] [Related]
3. Unveiling the biopathway for the design of novel COMT inhibitors.
Cruz-Vicente P; Gonçalves AM; Barroca-Ferreira J; Silvestre SM; Romão MJ; Queiroz JA; Gallardo E; Passarinha LA
Drug Discov Today; 2022 Oct; 27(10):103328. PubMed ID: 35907613
[TBL] [Abstract][Full Text] [Related]
4. Molecular recognition at the active site of catechol-O-methyltransferase (COMT): adenine replacements in bisubstrate inhibitors.
Ellermann M; Paulini R; Jakob-Roetne R; Lerner C; Borroni E; Roth D; Ehler A; Schweizer WB; Schlatter D; Rudolph MG; Diederich F
Chemistry; 2011 May; 17(23):6369-81. PubMed ID: 21538606
[TBL] [Abstract][Full Text] [Related]
5. Crystal Structure of Catechol O-Methyltransferase Complexed with Nitecapone.
Iijima H; Takebe K; Suzuki M; Kobayashi H; Takamiya T; Saito H; Niwa N; Kuwada-Kusunose T
Chem Pharm Bull (Tokyo); 2020; 68(5):447-451. PubMed ID: 32378542
[TBL] [Abstract][Full Text] [Related]
6. A semiempirical study on inhibition of catechol O-methyltransferase by substituted catechols.
Ovaska M; Yliniemelä A
J Comput Aided Mol Des; 1998 May; 12(3):301-7. PubMed ID: 9749372
[TBL] [Abstract][Full Text] [Related]
7. Structure-based design, synthesis, and in vitro evaluation of bisubstrate inhibitors for catechol O-methyltransferase (COMT).
Masjost B; Ballmer P; Borroni E; Zürcher G; Winkler FK; Jakob-Roetne R; Diederich F
Chemistry; 2000 Mar; 6(6):971-82. PubMed ID: 10785817
[TBL] [Abstract][Full Text] [Related]
8. Molecular modeling and metabolic studies of the interaction of catechol-O-methyltransferase and a new nitrocatechol inhibitor.
Palma PN; Bonifácio MJ; Loureiro AI; Wright LC; Learmonth DA; Soares-da-Silva P
Drug Metab Dispos; 2003 Mar; 31(3):250-8. PubMed ID: 12584150
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and evaluation of 3-hydroxypyridin-4-ones as inhibitors of catechol-O-methyltransferase.
de Beer J; Petzer JP; Lourens ACU; Petzer A
Mol Divers; 2021 May; 25(2):753-762. PubMed ID: 32108308
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of nitrocatechol chalcone and pyrazoline derivatives as inhibitors of catechol-O-methyltransferase and monoamine oxidase.
Hitge R; Smit S; Petzer A; Petzer JP
Bioorg Med Chem Lett; 2020 Jun; 30(12):127188. PubMed ID: 32299731
[TBL] [Abstract][Full Text] [Related]
11. Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility.
Kiss LE; Soares-da-Silva P
J Med Chem; 2014 Nov; 57(21):8692-717. PubMed ID: 25080080
[TBL] [Abstract][Full Text] [Related]
12. Kinetics and crystal structure of catechol-o-methyltransferase complex with co-substrate and a novel inhibitor with potential therapeutic application.
Bonifácio MJ; Archer M; Rodrigues ML; Matias PM; Learmonth DA; Carrondo MA; Soares-Da-Silva P
Mol Pharmacol; 2002 Oct; 62(4):795-805. PubMed ID: 12237326
[TBL] [Abstract][Full Text] [Related]
13. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase.
Engelbrecht I; Petzer JP; Petzer A
Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034
[TBL] [Abstract][Full Text] [Related]
14. Crystal structures of rat catechol-O-methyltransferase complexed with coumarine-based inhibitor.
Tsuji E; Okazaki K; Takeda K
Biochem Biophys Res Commun; 2009 Jan; 378(3):494-7. PubMed ID: 19056347
[TBL] [Abstract][Full Text] [Related]
15. The inhibition of catechol O-methyltransferase and monoamine oxidase by tetralone and indanone derivatives substituted with the nitrocatechol moiety.
de Beer AD; Legoabe LJ; Petzer A; Petzer JP
Bioorg Chem; 2021 Sep; 114():105130. PubMed ID: 34225162
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase.
Lautala P; Ulmanen I; Taskinen J
Mol Pharmacol; 2001 Feb; 59(2):393-402. PubMed ID: 11160877
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of ortho- and meta-nitrated inhibitors of catechol-O-methyltransferase: interactions with the active site and regioselectivity of O-methylation.
Palma PN; Rodrigues ML; Archer M; Bonifácio MJ; Loureiro AI; Learmonth DA; Carrondo MA; Soares-da-Silva P
Mol Pharmacol; 2006 Jul; 70(1):143-53. PubMed ID: 16618795
[TBL] [Abstract][Full Text] [Related]
18. Pharmacophore-based virtual screening of catechol-o-methyltransferase (COMT) inhibitors to combat Alzheimer's disease.
Patel CN; Georrge JJ; Modi KM; Narechania MB; Patel DP; Gonzalez FJ; Pandya HA
J Biomol Struct Dyn; 2018 Nov; 36(15):3938-3957. PubMed ID: 29281938
[TBL] [Abstract][Full Text] [Related]
19. Catechol-O-methyltransferase in complex with substituted 3'-deoxyribose bisubstrate inhibitors.
Ellermann M; Lerner C; Burgy G; Ehler A; Bissantz C; Jakob-Roetne R; Paulini R; Allemann O; Tissot H; Grünstein D; Stihle M; Diederich F; Rudolph MG
Acta Crystallogr D Biol Crystallogr; 2012 Mar; 68(Pt 3):253-60. PubMed ID: 22349227
[TBL] [Abstract][Full Text] [Related]
20. Characterization of non-nitrocatechol pan and isoform specific catechol-O-methyltransferase inhibitors and substrates.
Robinson RG; Smith SM; Wolkenberg SE; Kandebo M; Yao L; Gibson CR; Harrison ST; Polsky-Fisher S; Barrow JC; Manley PJ; Mulhearn JJ; Nanda KK; Schubert JW; Trotter BW; Zhao Z; Sanders JM; Smith RF; McLoughlin D; Sharma S; Hall DL; Walker TL; Kershner JL; Bhandari N; Hutson PH; Sachs NA
ACS Chem Neurosci; 2012 Feb; 3(2):129-40. PubMed ID: 22860182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
